EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY

Equipe constitutive du CERPOP, UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier
Brigitte TRÉTARRE •  chercheure



2023
  1. Satgé D, Habib-Hadef S, Otandault A, Samalin E, Trétarre B. Advocacy for colorectal cancer screening and awareness in people with intellectual disability. J Gastrointest Oncol. 2023 Jun 30;14(3):1650-1652. doi: 10.21037/jgo-22-998.
  2. Satgé D, Nishi M, Trétarre B. Assessing cancer in people with profound and multiple disabilities. BMC Cancer. 2023 Aug 25;23(1):798. doi: 10.1186/s12885-023-11313-3.
  3. Trétarre B, Dantony E, Coureau G, Defossez G, Guizard AV, Delafosse P, Daubisse L, Velten M, Karima Hammas, Barra S, Lapotre B, Plouvier S, d'Almeida T, Molinié F, Woronoff AS. Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women - A population-based study. Eur J Obstet Gynecol Reprod Biol. 2023 Apr;283:125-129. doi: 10.1016/j.ejogrb.2023.02.003.

2022
  1. Assogba ELF, Dumas A, Woronoff AS, Mollévi C, Coutant C, Ladoire S, Desmoulins I, Dabakuyo-Yonli TS; French Network of Cancer Registries (FRANCIM) (Trétarre B, Cowppli-Bony A, Daubisse-Marliac L, Molinié F. collaborators). Cross-sectional nationwide mixed-methods population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: the Candy study protocol. BMJ Open. 2022 Sep 28;12(9):e056834. doi: 10.1136/bmjopen-2021-056834.
  2. Bijoux W, Cordina-Duverger E, Balbolia S, Lamy PJ, Rebillard X, Tretarre B, Cenee S, Menegaux F. Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP). J Occup Med Toxicol. 2022 Feb 7;17(1):5. doi: 10.1186/s12995-022-00346-2.
  3. Borie F, Dubray V, Tretarre B. Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis. Clin Res Hepatol Gastroenterol. 2022 Mar;46(3):101856. doi: 10.1016/j.clinre.2021.101856.
  4. Compaoré ZC, Monnet E, Gérazime A, Molinié F, Guizard AV, Delafosse P, Dabakuyo-Yonli TS, Coureau G, Hammas K, Plouvier S, Bara S, Défossez G, Lapôtre-Ledoux B, Daubisse-Marliac L, d'Almeida T, Launoy G, Mansi L, Trétarre B, Woronoff AS. To what extent do age, stage and treatment influence survival after invasive cervical cancer: a French population-based study. Cancer Causes Control. 2022 Mar;33(3):403-415. doi: 10.1007/s10552-021-01536-9.
  5. Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C; CONCORD Working Group (Trétarre B collaborator). Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol. 2022 Nov 10:noac217. doi: 10.1093/neuonc/noac217. Epub ahead of print.
  6. Lesage C, Habib-Hadef S, Trétarre B, Lesage FX, Bessaoud F, Varey E, Guillot B, Satgé D. Melanoma and intellectual disability: do prognostic factors at diagnosis differ from general population? J Intellect Disabil Res. 2022 Apr;66(4):392-398. doi: 10.1111/jir.12915.
  7. Poiseuil M, Tron L, Woronoff AS, Trétarre B, Dabakuyo-Yonli TS, Fauvernier M, Roche L, Dejardin O, Molinié F, Launoy G; French Network of Cancer Registries (FRANCIM). How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France? Int J Cancer. 2022 Jan 15;150(2):253-262. doi: 10.1002/ijc.33803.
  8. Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard JL, Girardi F, Fowler C, Marcos-Gragera R, Bonaventure A, Saint-Jacques N, Minicozzi P, De P, Rodríguez-Barranco M, Larønningen S, Di Carlo V, Mägi M, Valkov M, Seppä K, Wyn Huws D, Coleman MP, Allemani C; CONCORD Working Group (Trétarre B collaborator). Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. Lancet Child Adolesc Health. 2022 Jun;6(6):409-431. doi: 10.1016/S2352-4642(22)00095-5.
  9. Trétarre B, Trouche-Sabatier SG, Foucan AS, Abdo N, Poinas G, Rébillard X, Azria D, Iborra F. L’adhésion des urologues aux recommandations du comité de cancérologie de l’association Française d’urologie (CCAFU) dans le bilan d’imagerie du cancer localisé de la prostate [Adhesion of urologists to the recommendations of the French Urological Association Cancer Committee (CCAFU) in the imaging work-up of localized prostate cancer]. Prog Urol. 2022 Dec;32(16):1446-1454. French. doi: 10.1016/j.purol.2022.09.021.
  10. Vener C, Rossi S, Minicozzi P, Marcos-Gragera R, Poirel HA, Maynadié M, Troussard X, Pravettoni G, De Angelis R, Sant M; EUROCARE-6 Working Group (Cowppli-Bony A, Trétarre B, Molinié F collaborators). Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials. Front Oncol. 2022 Jul 14;12:892684. doi: 10.3389/fonc.2022.892684.
2021
  1. Baicry F, Molinié F, Plouvier S, Colonna M, Daubisse-Marliac L, Grosclaude P, Trétarre B, Bara S, Lapôtre-Ledoux B, Woronoff AS, Guizard AV, Bouvier V, Troussard X, Marrer E, Klein D, Velten M, Jégu J. What is the most appropriate period to define synchronous cancers? Cancer Epidemiol. 2021 Apr;71(Pt A):101900. doi: 10.1016/j.canep.2021.101900.
  2. Defossez G, Uhry Z, Delafosse P, Dantony E, d'Almeida T, Plouvier S, Bossard N, Bouvier AM, Molinié F, Woronoff AS, Colonna M, Grosclaude P, Remontet L, Monnereau A; French Network of Cancer Registries (FRANCIM) (Trétarre B, Grosclaude P, Cowppli-Bony A collaborators). Cancer incidence and mortality trends in France over 1990-2018 for solid tumors: the sex gap is narrowing. BMC Cancer. 2021 Jun 24;21(1):726. doi: 10.1186/s12885-021-08261-1.
  3. Girardi F, Rous B, Stiller CA, Gatta G, Fersht N, Storm HH, Rodrigues JR, Herrmann C, Marcos-Gragera R, Peris-Bonet R, Valkov M, Weir HK, Woods RR, You H, Cueva PA, De P, Di Carlo V, Johannesen TB, Lima CA, Lynch CF, Coleman MP, Allemani C; CONCORD Working Group (Trétarre B, Grosclaude P collaborators). The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). Neuro Oncol. 2021 Oct 1;23(10):1765-1776. doi: 10.1093/neuonc/noab067.
  4. Hutin M, Trétarre B, Gras C, Bessaoud F, Daurès JP, Delbos O, Bringer JP, Ayuso D, Thuret R, Azria D, Serre I, Brel D, Reis Borges R, Iborra F, Rébillard X; et tous les acteurs de l’onco-urologie de l’Hérault. Le cancer du rein dans le département de L’Hérault : résultats de 30 ans d’enregistrement [Renal cell carcinoma in the department of Hérault: Results over a 30 year period]. Prog Urol. 2021 Mar;31(3):175-182. French. doi: 10.1016/j.purol.2020.10.001.
  5. Picart T, Meyronet D, Pallud J, Dumot C, Metellus P, Zouaoui S, Berhouma M, Ducray F, Bauchet L, Guyotat J; French Brain Tumor DataBase (Trétarre B collaborators)..; Club de Neuro-Oncologie of the Société Française de Neurochirurgie. Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma. J Cancer Res Clin Oncol. 2021 Jun;147(6):1843-1856. doi: 10.1007/s00432-020-03474-6.
  6. Pujol JL, Thomas PA, Giraud P, Denis MG, Tretarre B, Roch B, Bommart S. Lung Cancer in France. J Thorac Oncol. 2021 Jan;16(1):21-29. doi: 10.1016/j.jtho.2020.09.012.
  7. Raze T, Lacour B, Cowppli-Bony A, Delafosse P, Velten M, Trétarre B, Defossez G, Hammas K, Woronoff AS, Ganry O, Plouvier S, Coureau G, Guizard AV, Bara S, Monnereau A, Daubisse-Marliac L, Troussard X, D'Almeida T, Baldi I, Bouvier V, Boissel N, Clavel J, Desandes E. Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival. J Adolesc Young Adult Oncol. 2021 Feb;10(1):29-45. doi: 10.1089/jayao.2020.0017.
  8. Séverin D, Bessaoud F, Meftah N, Du Thanh A, Tretarre B, Guillot B, Makinson A. A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma. AIDS. 2021 Mar 1;35(3):399-405. doi: 10.1097/QAD.0000000000002744.
  9. Xiao D, Guizard AV, Daubisse-Marliac L, Woronoff AS, Trétarre B, Delafosse P, Molinié F, Cowppli-Bony A, Lapôtre-Ledoux B, Bara S, Marrer E, Velten M, Laroche L, Heutte N, Grosclaude P, Joly F. Evaluation of long-term living conditions in patients treated for localised prostate cancer. Eur J Cancer Care (Engl). 2021 Jan;30(1):e13333. doi: 10.1111/ecc.13333.
  10. Zarka M, Tretarre B, Rebillard X, Murez T, Daures JP, Azria D, Serre I, Brel D, Ramay AS, Reis Borges R, Gevorgyan A, Hutin M, Marchal S, Korahanis N, Iborra F, Thuret R; tous les acteurs de l’onco-urologie de l’Hérault. Le cancer des organes génitaux externes de l’homme dans le département de l’Hérault: résultats de 30 ans d’enregistrement du registre des tumeurs de l’Hérault (1987–2016) [Cancers of the external genital organs of male in Hérault: Results from the Hérault tumor register (RTH) over a period of 30 years (1987-2016)]. Prog Urol. 2021 Apr;31(5):282-292. French. doi: 10.1016/j.purol.2020.08.054.
2020
  1. Barul C, Matrat M, Auguste A, Dugas J, Radoï L, Menvielle G, Févotte J, Guizard AV, Stücker I, Luce D; ICARE study group (Trétarre B collaborator). . Welding and the risk of head and neck cancer: the ICARE study. Occup Environ Med. 2020 May;77(5):293-300. doi: 10.1136/oemed-2019-106080.
  2. Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, Maciejczyk A, Rodríguez-Barranco M, Zadnik V, Minicozzi P; EUROCARE-5 Working Group (Trétarre B collaborator). Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study. Arch Gynecol Obstet. 2020 Feb;301(2):591-602. doi: 10.1007/s00404-019-05412-5.
  3. Bouvier AM, Robaszkiewicz M, Jooste V, Cariou M, Drouillard A, Bouvier V, Nousbaum JB; French Network of Cancer Registries (FRANCIM) (Trétarre B, Molinié F, Cowppli-Bony A collaborators). Trends in incidence of small bowel cancer according to histology: a population-based study. J Gastroenterol. 2020 Feb;55(2):181-188. doi: 10.1007/s00535-019-01636-z.
  4. Houédé N, Rébillard X, Bouvet S, Kabani S, Fabbro-Peray P, Trétarre B, Ménégaux F. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer. 2020 Aug 12;20(1):757. doi: 10.1186/s12885-020-07244-y.
  5. Lavalette C, Cordina Duverger E, Artaud F, Rébillard X, Lamy PJ, Trétarre B, Cénée S, Menegaux F. Body mass index trajectories and prostate cancer risk: Results from the EPICAP study. Cancer Med. 2020 Sep;9(17):6421-6429. doi: 10.1002/cam4.3241.
  6. Ng S, Zouaoui S, Bessaoud F, Rigau V, Roux A, Darlix A, Bauchet F, Mathieu-Daudé H, Trétarre B, Figarella-Branger D, Pallud J, Frappaz D, Roujeau T, Bauchet L. An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013. Neuro Oncol. 2020 Jun 9;22(6):851-863. doi: 10.1093/neuonc/noz227.
  7. Sant M, Meneghini E, Bastos J, Rossi PG, Guevara M, Innos K, Katalinic A, Majuelo LG, Marcos-Gragera R, Molinié F, Rapiti E, Vizcaino A, Zadnik V, Minicozzi P; European High Resolution Working Group on breast cancer (Trétarre B collaborator).  Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. Breast Cancer Res Treat. 2020 Sep;183(2):439-450. doi: 10.1007/s10549-020-05761-9.
  8. Satgé D, Axmon A, Trétarre B, Sandberg M, Ahlström G. Cancer diagnoses among older people with intellectual disability compared with the general population: a national register study. J Intellect Disabil Res. 2020 Aug;64(8):579-588. doi: 10.1111/jir.12734.
  9. Trouche-Sabatier SG, Rebillard X, Iborra F, Azria D, Daures JP, Poinas G, Abdo N, Delbos O, Gevorgyan A, Marchal S, Guillon R, Millet I, Lamy PJ, Lauche O, Reis-Borges R, Serre I, Topart D, Tretarre B; tous les acteurs de l’onco-urologie de l’Hérault. RHESOU (Registre de l’Hérault spécialisé en onco-urologie) : le premier registre français spécialisé en onco-urologie. Un outil méthodologique de recueil de données en onco-urologie. Bilan de faisabilité sur un an d’expérience [RHESOU (Registry in HErault Specialized in Onco-Urology) : the first French Registry specialized in Onco-Urology. One-year experience]. Prog Urol. 2020 Dec;30(16):1038-1044. French. doi: 10.1016/j.purol.2020.09.015.
  10. Villers A, Bessaoud F, Trétarre B, Grosclaude P, Malavaud B, Rebillard X, Iborra F, Daubisse L, Malavaud S, Roobol M, Heijnsdijk EA, de Koning HJ, Hugosson J, Rischmann P, Soulié M. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). Prog Urol. 2020 Apr;30(5):252-260. doi: 10.1016/j.purol.2020.02.011.
  11. Wendeu-Foyet MG, Cénée S, Koudou Y, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Boland A, Olaso R, Deleuze JF, Blanché H, Lamy PJ, Mulot C, Laurent-Puig P, Truong T, Menegaux F. Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study. Int J Cancer. 2020 Dec 1;147(11):3119-3129. doi: 10.1002/ijc.33139.